Surrozen Q3: $129.7M Non-Cash Loss, Boehringer Arbitration Disclosed, Cash Into 2029
SRZN has more than doubled off its 52-week low of $11.51 on light trading volume (0.2× avg).
Summary
Surrozen's Q3 loss was $129.7 million, but $113.0 million of that was non-cash warrant and tranche remeasurement. The filing also reveals Boehringer Ingelheim has filed for arbitration over their collaboration, while October financings push the cash runway into 2029.
Key Events · Earnings and Guidance · SRZN
-
Q3 Loss Is Mostly Non-Cash
Net loss of $129.7 million for Q3 2026 included $113.0 million of non-cash losses on changes in fair value of tranche and warrant liabilities, driven primarily by the increase in the stock price — not a cash outflow.
-
Boehringer Files ICC Arbitration
In October 2026 Boehringer Ingelheim filed an ICC arbitration request alleging material breach of the CLA and seeking a 50% cut to royalty and milestone obligations plus repayment of $5.0 million of the June 2026 milestone; Surrozen denied the claims in full in November 2026.
-
$5.0M Milestone Constrained
Surrozen recognized only $5.0 million of the $10.0 million June 2026 development milestone (a 50% reduction) and booked the remaining $5.0 million received in September 2026 as accrued liabilities rather than revenue.
-
Cash Runway Extended Into 2029
Cash and cash equivalents were $100.4 million at September 30, 2026; October 2026 brought $95.1 million gross from the 2025 PIPE second tranche, $29.8 million net from 2026 ATM sales and $1.1 million from warrant exercises, funding operations into 2029.
Analysis · SRZN · Life Sciences
The $129.7 million Q3 net loss is almost entirely accounting noise: $113.0 million of it is non-cash remeasurement of the tranche and warrant liabilities, driven by the rising share price rather than any cash outflow. The real news buried in the 10-Q is that Boehringer Ingelheim has taken Surrozen to ICC arbitration, seeking to halve its royalty and milestone obligations and claw back $5.0 million of the June 2026 milestone. Surrozen has already stopped counting that $5.0 million as revenue and parked it in accrued liabilities, so a chunk of the partnership economics is now contested. Against that, the balance sheet is solid: $100.4 million of cash at quarter-end plus roughly $126 million raised in October (the $95.1 million PIPE tranche, $29.8 million of ATM sales and $1.1 million of warrant exercises) funds operations into 2029, covering the DUET Phase 1b/2a readouts.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $32.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.1M. The 52-week trading range was $11.51 to $37.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.